Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms

Area of Science:

• Pediatric Allergy and Immunology
• Otolaryngology
• Medical Device Research

Background:

• Allergic rhinitis (AR) significantly impacts children's quality of life.
• Effective symptomatic management is crucial for pediatric patients.
• Current treatments include topical corticosteroids, with varying safety profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of Narivent(®) compared to topical corticosteroids for AR symptom management in children.
• To assess the impact of Narivent(®) on key AR symptoms including nasal congestion, rhinorrhoea, sneezing, and nasal itching.
• To determine if Narivent(®) offers a favorable safety profile in pediatric AR treatment.

Main Methods:

• A randomized, two-arm study involving 40 pediatric patients diagnosed with AR.
• Participants received either Narivent(®) or topical intranasal corticosteroids (one puff per nostril, twice daily for 30 days).
• Symptom severity was subjectively assessed using a 0-100 mm visual analogue scale.

Main Results:

• Narivent(®) treatment led to significant improvements in nasal congestion, rhinorrhoea, and sneezing after 30 days.
• Topical corticosteroids also significantly reduced the severity of all assessed subjective symptoms.
• Narivent(®) showed comparable efficacy to intranasal corticosteroids in managing major AR symptoms.

Conclusions:

• Narivent(®) is effective for treating nasal congestion and other major symptoms in children with AR over a 30-day period.
• The medical device demonstrated comparable results to intranasal corticosteroids.
• Narivent(®) presents a potentially better safety profile for pediatric AR management.